Vedolizumab

CAS No.	943609-66-3	Cat. No.	BCP26256
Name	Vedolizumab
Synonyms	MLN-02; LDP-02; MLN0002;Anti-Human lymphocyte α4β7 integrin, Humanized Antibody;
Formula	C6528H10072N1732O2042S42	M. Wt	146834.53

Description	Vedolizumab is a monoclonal antibody binds to integrin α4β7. Vedolizumab blocks the α4β7 integrin, results in gut-selective anti-inflammatory activity. Vedolizumab binds to memory CD4(+) T and B lymphocytes with subnanomolar potency (EC(50) = 0.3-0.4 nM). Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels. Vedolizumab selectively inhibits adhesion of alpha(4)beta(7)-expressing cells to mucosal addressin cell adhesion molecule 1 (median inhibition concentration [IC(50)] = 0.02-0.06 microg/ml) and fibronectin (IC(50) = 0.02 microg/ml), but not vascular cell adhesion molecule.
Pathways	Angiogenesis/Protein Tyrosine Kinase
Targets	Integrin

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.